Terril Brothers Inc. Sells 6,245 Shares of Bristol-Myers Squibb Co (NYSE:BMY)

Terril Brothers Inc. cut its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 464,354 shares of the biopharmaceutical company’s stock after selling 6,245 shares during the period. Bristol-Myers Squibb comprises approximately 6.7% of Terril Brothers Inc.’s portfolio, making the stock its 4th largest position. Terril Brothers Inc.’s holdings in Bristol-Myers Squibb were worth $21,058,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. FMR LLC boosted its position in Bristol-Myers Squibb by 313.9% during the 1st quarter. FMR LLC now owns 40,851,887 shares of the biopharmaceutical company’s stock worth $1,949,043,000 after buying an additional 30,981,844 shares during the period. Janus Henderson Group PLC boosted its position in Bristol-Myers Squibb by 75.7% during the 2nd quarter. Janus Henderson Group PLC now owns 16,156,559 shares of the biopharmaceutical company’s stock worth $732,691,000 after buying an additional 6,960,047 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Bristol-Myers Squibb by 1.1% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,251,891 shares of the biopharmaceutical company’s stock worth $328,873,000 after buying an additional 78,260 shares during the period. Nordea Investment Management AB boosted its position in Bristol-Myers Squibb by 380.2% during the 1st quarter. Nordea Investment Management AB now owns 6,252,847 shares of the biopharmaceutical company’s stock worth $298,324,000 after buying an additional 4,950,748 shares during the period. Finally, California Public Employees Retirement System boosted its position in Bristol-Myers Squibb by 14.3% during the 1st quarter. California Public Employees Retirement System now owns 5,118,016 shares of the biopharmaceutical company’s stock worth $244,181,000 after buying an additional 642,267 shares during the period. Institutional investors and hedge funds own 80.11% of the company’s stock.

BMY has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a research report on Tuesday, May 7th. UBS Group dropped their price target on shares of Bristol-Myers Squibb from $55.00 to $51.00 and set a “neutral” rating on the stock in a research report on Thursday, June 13th. Atlantic Securities upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target on the stock in a research report on Wednesday, August 14th. ValuEngine downgraded shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 2nd. Finally, Barclays upgraded shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $53.00 to $55.00 in a research report on Friday, May 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $55.88.

Shares of NYSE:BMY traded down $0.02 during mid-day trading on Wednesday, hitting $47.61. The company had a trading volume of 4,069,694 shares, compared to its average volume of 14,823,283. The firm has a fifty day moving average price of $45.47 and a 200 day moving average price of $47.44. The company has a market capitalization of $76.85 billion, a PE ratio of 11.96, a price-to-earnings-growth ratio of 2.33 and a beta of 0.73. The company has a debt-to-equity ratio of 1.51, a current ratio of 3.88 and a quick ratio of 3.75. Bristol-Myers Squibb Co has a one year low of $42.48 and a one year high of $63.69.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 EPS for the quarter, beating the Zacks’ consensus estimate of $1.06 by $0.12. The business had revenue of $6.27 billion during the quarter, compared to analyst estimates of $6.10 billion. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. Bristol-Myers Squibb’s quarterly revenue was up 10.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.01 EPS. Research analysts expect that Bristol-Myers Squibb Co will post 4.26 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were paid a dividend of $0.41 per share. The ex-dividend date was Wednesday, July 3rd. This represents a $1.64 dividend on an annualized basis and a yield of 3.44%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.

In other Bristol-Myers Squibb news, Director Robert J. Bertolini purchased 11,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was acquired at an average price of $44.72 per share, for a total transaction of $491,920.00. Following the purchase, the director now owns 11,397 shares of the company’s stock, valued at approximately $509,673.84. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.13% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: Average Daily Trade Volume – What You Need to Know

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.